A survey conducted by the professional services firm, Ernst & Young, has found that CFOs of pharmaceutical companies considered global cost reduction as one of the key priorities for their businesses, according to PJB news.
Subscribe to our email newsletter
According to the survey, 92% of respondents rated global cost reduction as a key issue, while 56% felt it was the role of CFOs to lead cost reduction initiatives. The CFOs also believed that competitive pressures (58%), profitability (58%), and the need for better returns for investors (33%) were the major drivers for cost reduction. The respondents (74%) also agreed that CFOs have to shift their focus from low-value functions like defensive monitoring and reporting to a focus on partnering to help shape growth strategies.
The survey also revealed that factors like increased regulatory and compliance requirements (46%), increased corporate governance obligations (36%) and increasing risk management responsibilities (32%) played a major part in transforming the role of CFOs.
The Economist Intelligence Unit, which conducted the global survey on behalf of Ernst & Young, surveyed 95 CEOs, CFOs, chief information officers and other board level executives. Respondents represented Western Europe (46%), Asia Pacific (22%), North America (19%), and other areas (15%).
But a survey of pharmaceutical CFOs in India found that human resource challenges were major priorities for CFOs in multinational companies (MNC), with 67% ranking employee attrition as a key concern versus only 25% of respondents in India-based pharmaceutical companies. The respondents in both groups considered bottom-line pressures as a key concern (76% overall), although the focus of their cost-cutting efforts differed. CFOs of Indian companies were found to be more concerned about reducing costs in the supply chain (67%) compared with 44% of MNC CFOs.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.